Treatment and Drug Resistance to Helicobacter Pylori: A Brief Review

doi:10.33696/gastroenterology.2.031

Abstract

Helicobacter pylori is a gram-negative, spiral-shaped bacterium that inhabits the gastric environment of 60.3% of the global population [1]. Though most individuals infected with the bacterium remain asymptomatic, it is known that this infection plays a pivotal role in the development of diseases such as chronic gastritis, peptic ulcer, gastric cancer and gastric MALT lymphoma

Highlights

Helicobacter pylori is a gram-negative, spiral-shaped bacterium that inhabits the gastric environment of 60.3% of the global population [1]
Introduction, amoxicillin (1000 mg, BID), metronidazole (500 mg, BID) and clarithromycin (500 mg, BID) for 10-14 days is recommended in regions where bismuth is not available [9,10,11]
In the late 1990s, triple therapy with clarithromycin (500 mg), metronidazole (500 mg) or amoxicillin (1000 mg), and proton pump inhibitors (PPIs) in standard doses twice a day for 7 to 10 days became the first-line regimen for eradication of H. pylori in many countries

Summary

Introduction

(standard dose, BID), amoxicillin (1000 mg, BID), metronidazole (500 mg, BID) and clarithromycin (500 mg, BID) for 10-14 days is recommended in regions where bismuth is not available [9,10,11]. In the late 1990s, triple therapy with clarithromycin (500 mg), metronidazole (500 mg) or amoxicillin (1000 mg), and proton pump inhibitors (PPIs) in standard doses twice a day for 7 to 10 days became the first-line regimen for eradication of H. pylori in many countries. The main guidelines for the treatment of H. pylori infection, currently recommend quadruple bismuth therapy (QBT) for first-line treatment, in preference to triple therapy, restricted to areas with low rates of resistance to clarithromycin (

Drug Resistance

Novel Therapy Options

Future Perspectives

Findings

Conclusion